JP2024533119A5 - - Google Patents
Info
- Publication number
- JP2024533119A5 JP2024533119A5 JP2024513740A JP2024513740A JP2024533119A5 JP 2024533119 A5 JP2024533119 A5 JP 2024533119A5 JP 2024513740 A JP2024513740 A JP 2024513740A JP 2024513740 A JP2024513740 A JP 2024513740A JP 2024533119 A5 JP2024533119 A5 JP 2024533119A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240342P | 2021-09-02 | 2021-09-02 | |
| US63/240,342 | 2021-09-02 | ||
| PCT/EP2022/074455 WO2023031403A1 (en) | 2021-09-02 | 2022-09-02 | Antibodies for the treatment of aml |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533119A JP2024533119A (ja) | 2024-09-12 |
| JP2024533119A5 true JP2024533119A5 (enExample) | 2025-09-04 |
Family
ID=83438540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513740A Pending JP2024533119A (ja) | 2021-09-02 | 2022-09-02 | Ａｍｌの治療のための抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240352136A1 (enExample) |
| EP (1) | EP4396230A1 (enExample) |
| JP (1) | JP2024533119A (enExample) |
| CN (1) | CN117916266A (enExample) |
| TW (1) | TW202319400A (enExample) |
| WO (1) | WO2023031403A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2480671B8 (en) | 2009-09-22 | 2015-10-28 | ProBioGen AG | Process for producing molecules containing specialized glycan structures |
| GB201507827D0 (en) * | 2015-05-07 | 2015-06-17 | Adc Therapeutics Sarl | Diagnostic test |
| KR20190017735A (ko) | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| EP3649153B8 (en) | 2017-07-06 | 2025-07-16 | Tusk Therapeutics Ltd | Fc optimised anti-cd25 antibodies for tumor specific cell depletion |
| KR102097449B1 (ko) | 2017-07-17 | 2020-04-06 | 성균관대학교산학협력단 | 복수의 층간 인터락킹 구조를 포함하는 건식 접착 시스템 |
| KR101930470B1 (ko) | 2017-07-20 | 2019-03-14 | (주)파트론 | 지문 센서 패키지 |
| KR102570856B1 (ko) | 2017-07-21 | 2023-08-25 | 상라오 징코 솔라 테크놀러지 디벨롭먼트 컴퍼니, 리미티드 | 페로브스카이트 태양전지 및 이를 포함하는 탬덤 태양전지 |
| KR20190069030A (ko) | 2017-12-11 | 2019-06-19 | 삼성전자주식회사 | 디스플레이 장치 및 그 제어 방법 |
| US10752691B2 (en) | 2018-03-13 | 2020-08-25 | Tusk Therapeutics Ltd. | Anti-CD25 antibody agents |
| TWI848030B (zh) * | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
| CN114302746A (zh) * | 2019-06-10 | 2022-04-08 | Adc治疗有限公司 | 包含抗cd25抗体药物缀合物和另一剂的组合疗法 |
-
2022
- 2022-09-02 US US18/687,561 patent/US20240352136A1/en active Pending
- 2022-09-02 TW TW111133446A patent/TW202319400A/zh unknown
- 2022-09-02 EP EP22776886.8A patent/EP4396230A1/en active Pending
- 2022-09-02 JP JP2024513740A patent/JP2024533119A/ja active Pending
- 2022-09-02 WO PCT/EP2022/074455 patent/WO2023031403A1/en not_active Ceased
- 2022-09-02 CN CN202280059128.8A patent/CN117916266A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024533119A5 (enExample) | ||
| KR102291971B1 (ko) | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 | |
| AU2022243870A1 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| AU2021203126A1 (en) | Anti-GITR antibodies and methods of use thereof | |
| EP4074732A1 (en) | Fully human antibodies against ox40, method for preparing the same, and use thereof | |
| RU2625222C2 (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| TW201902514A (zh) | Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| US20230220106A1 (en) | Antibodies targeting 5t4 and uses thereof | |
| AU2016311136B2 (en) | Combinations and uses thereof | |
| Robak et al. | Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia | |
| TW202330038A (zh) | 用於治療癌症之ｂ７－ｈ４抗體－藥物結合物 | |
| CN115210261B (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| EP3896089A1 (en) | Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases | |
| TW202216193A (zh) | 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法 | |
| KR20250039386A (ko) | 항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법 | |
| KR20230048112A (ko) | Cd40 효능성 항체 및 이의 사용 방법 | |
| CN118324910A (zh) | Ccr8抗体的应用 | |
| RU2788092C2 (ru) | Молекулы антител к pd-1 и их применения | |
| HK40082317A (en) | Fully human antibodies against ox40, method for preparing the same, and use thereof | |
| HK40051088A (en) | Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases | |
| CN112439060A (zh) | Pd-l1免疫疗法的新用途 | |
| HK40019885A (en) | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer | |
| HK1247122B (en) | Combinations and uses thereof |